o11 Biomedical raises €2.5M Seed round
12 March 2024· Aachen, Germany· health, biotech, materials, b2b, deep_hardware
The EIC Accelerator grant will be used to demonstrate clinical evidence of the effectiveness of the RESPILIQ device, accelerate its development, and pave the way for market approval.
Investors
LeadEuropean Innovation Council
About o11 Biomedical
Stage
Seed
Headquarters
Aachen, Germany
Founded
2022
Team Size
6–20
Sectors
healthbiotechmaterialsb2bdeep_hardware
Source: https://ffund.nl/o11-biomedical-secures-e2-5m-from-the-eic-accelerator-to-develop-respiliq/